Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

• Research unit: INNOSUISSE
• Project number: 13265.1 PFLS-LS

Short description (German)

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Short description (English)

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Abstract (German)

Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.

Abstract (English)

Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.